I n the February issue, Han et al 1 present the use of a novel clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated 9 (Cas9) method to inactivate the calponin-1 gene involved in smooth muscle contraction, by introducing a knockin mutation to cleanly disrupt a CC(A/T)6GG (CArG) element in the first intron of the gene. Previous work by the group had suggested a critical role of the CArG element in calponin-1 gene expression in both humans and mice. 2 Here, the authors injected the components of CRISPR-Cas9-an mRNA for the Cas9 endonuclease, a guide RNA containing the 20-nucleotide sequence matching the sequence of the CArG element, and a 135-nucleotide single-strand DNA oligonucleotide overlapping the CArG element and containing the desired knockin mutation-into the cytoplasm of fertilized mouse eggs ( Figure) . This resulted in stable incorporation of the CArG knockin mutation into the genome in some of the eggs. After implantation of the resulting blastocysts into surrogate mothers, the injected eggs yielded founder mice in 3 weeks. Remarkably, 3 of 18 founder mice (17%) carried the desired knockin mutation on ≥1 chromosome, with 1 founder having the mutation on both chromosomes. The founder mice were successfully bred, with germline transmission of the knockin mutation. With calponin-1 being a smooth muscle cell-restricted gene, the authors examined smooth muscle tissues from wild-type, heterozygous, and homozygous mice and found almost complete suppression of calponin-1 gene expression in the homozygous mice. This simple yet elegant experiment, performed within a time frame of a few months, unequivocally establishes the critical role of the CArG element in calponin-1 gene expression in smooth muscle tissues.
See accompanying article on page 312 in the February 2015 issue
To fully appreciate the game-changing nature of CRISPR-Cas9, consider a similar study performed in the pregenomeediting era. Khromov et al 3 engineered a knockin mouse in which a 30-nucleotide fragment containing an AT-rich sequence and a CArG element was deleted to suppress telokin gene expression in smooth muscle tissues. This entailed a long series of steps. First, a double-strand targeting vector containing 6-kb and 3-kb homology arms flanking an antibiotic resistance cassette (replacing the 30-nucleotide fragment and flanked by loxP sequences) was produced. Second, the targeting vector was electroporated into mouse embryonic stem cells, which were selected with antibiotic and then expanded. Third, mouse embryonic stem cell clones were screened for correct insertion of the antibiotic resistance cassette into the telokin locus. Fourth, embryonic stem cells were injected into blastocysts and implanted into surrogate mothers to yield chimeric mice. Fifth, the chimeric mice were bred to obtain mice that had inherited the mutant allele through the germline. Sixth, as part of the breeding, male mice expressing Cre recombinase in the germline were used to remove the antibiotic resistance cassette. Finally, the floxed alleles were bred to homozygosity to yield the final mice for study. A conservative estimate of the amount of time required to carry out all these steps is ≥1 year and probably ≈2 years; yet, despite all this effort, the end result was a mutant allele in which the 30-nucleotide CArG-bearing fragment was replaced with a 34-nucleotide loxP sequence, effective but crude. In contrast, Han et al 1 were able to carry out their study in just a few months while creating a more subtle mutant allele in which several nucleotides were substituted to impair the CArG element, with no need for antibiotic resistance, the Cre-loxP system, and so on.
The tremendous use of CRISPR-Cas9 in generating knockout and knockin mice was initially demonstrated by Rudolf Jaenisch's group 4, 5 and has since been validated with its ability to correct pathogenic mutations in mouse embryos 6, 7 and to generate knockout and knockin mutations in a wide variety of model organisms, most impressively in monkeys. 8 The work by Han et al 1 represents the first case in which CRISPR-Cas9 has been used to manipulate smooth muscle gene expression by editing a key noncoding regulatory element and can easily be extended to rapidly and efficiently interrogate the function of any number of noncoding regulatory elements throughout the mouse genome. This successful demonstration of the method should have a long-time impact not only in the field of smooth muscle biology but also in many other fields of biomedical research.
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Figure.
Accelerated generation of knockin mice with clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated 9 (Cas9). PCR indicates polymerase chain reaction.
